Hepatitis C Antiviral Resistance in African-Americans
This study has been completed.
Sponsor:
Information provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier:
NCT00038974
First received: June 5, 2002
Last updated: March 15, 2011
Last verified: March 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is designed to test the hypothesis that African-Americans respond less well to combination pegylated interferon and ribavirin therapy than Caucasian-Americans who have chronic hepatitis C genotype 1 and who were not previously treated with either interferon or ribavirin. Reasons for differences in response, regardless of race, will be studied.
| Condition | Intervention | Phase |
|---|---|---|
|
Hepatitis C |
Drug: Pegylated interferon Drug: Ribavirin |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (Virahep-C) |
Resource links provided by NLM:
Further study details as provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion:
- Age between 18 and 70 years at screening
- Black/African American or White/Caucasian
- Born in the United States
- Quantifiable Serum HCV RNA
- Hepatitis C genotype 1
- Liver biopsy consistent with chronic hepatitis C
- Negative urine pregnancy test
- Males and Females must be using two reliable forms of effective contraception while on drug and during follow-up.
Exclusion:
- Previous treatment with interferon or ribavirin
- Positive test at screening for anti-HIV
- Positive test for HBsAg
- Alcohol consumption of more than two drinks/day
- History of other chronic liver disease
- Pregnant or breast-feeding women
- Male partners of women who are pregnant or contemplating pregnancy
- Neutrophil count <1000 cells/mm3
- Hgb <11 g/dl in women or 12 g/dl in men
- Platelet count <75,000 cells/mm3.
- Thalassemia, spherocytosis, history of GI bleeding or those at increased risk of anemia
- Serum creatinine level >1.5 times the upper limit of normal at screening or CrCl < 75cc/min
- Current dialysis
- Alcohol or drug abuse within 6 months
- Current (<6 months)severe psychiatric disorder
- History of immunologically mediated disease
- Decompensated liver disease
- High risk cardiovascular/coronary artery disease
- Severe seizure disorder or anticonvulsant use
- Solid organ or bone marrow transplantation
- Thyroid disease poorly controlled on prescribed medications
- History or other evidence of retinopathy
- Chronic use of oral steroids
- Inability or unwillingness to provide informed consent or abide by the study protocol
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00038974
Locations
| United States, California | |
| University of California, San Francisco | |
| San Francisco, California, United States, 94143 | |
| United States, Florida | |
| University of Miami School of Medicine | |
| Miami, Florida, United States, 33136 | |
| United States, Illinois | |
| Rush University | |
| Chicago, Illinois, United States, 60612 | |
| United States, Maryland | |
| University of Maryland School of Medicine | |
| Baltimore, Maryland, United States, 21201 | |
| United States, Massachusetts | |
| Beth Israel Deaconess Medical Center | |
| Boston, Massachusetts, United States, 02215 | |
| United States, Michigan | |
| University of Michigan Medical Center | |
| Ann Arbor, Michigan, United States, 48109 | |
| United States, New York | |
| New York-Presbyterian Medical Center | |
| New York, New York, United States, 10032 | |
| United States, North Carolina | |
| University of North Carolina | |
| Chapel Hill, North Carolina, United States, 27599 | |
Sponsors and Collaborators
More Information
Additional Information:
No publications provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00038974 History of Changes |
| Other Study ID Numbers: | Virahep-C (completed), U01 DK60329 |
| Study First Received: | June 5, 2002 |
| Last Updated: | March 15, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):
|
Hepatitis C Interferon Ribavirin Efficacy |
Viral load Genetics Cytokines Immunology |
Additional relevant MeSH terms:
|
Hepatitis Hepatitis A Hepatitis C Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Enterovirus Infections Picornaviridae Infections RNA Virus Infections |
Flaviviridae Infections Antiviral Agents Interferons Ribavirin Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Antineoplastic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 23, 2013